Comparative genomics of primary prostate cancer and paired metastases: insights from 12 molecular case studies.

"Conflict of interest statement: The University of Michigan and Harvard have a patent in the field of diagnostics and therapeutics for ETS gene fusion prostate cancer; ST, FD, and MAR are named as co‐inventors. The diagnostic field of use was licensed to Hologic/Gen‐Probe (who sublicensed some rights to Ventana/Roche) and is licensed to LynxDx. Cornell University has a patent on SPOP prostate cancer mutations in the field of diagnostics and therapeutics; MAR is a co‐inventor. MAR serves on the Scientific Advisory Board of Neogenomics. ST is a co‐inventor on a patent issued to Strata Oncology related to MSI determination and checkpoint inhibitor benefit. ST has the following other conflicts of interest: Employment (Strata Oncology); Leadership (Strata Oncology), Stock and Other Ownership Interests (Strata Oncology, Javelin Oncology); Consulting or Advisory Roles (Janssen, Astellas Medivation, Strata Oncology); Research Funding (Astellas Medivation); Travel, accommodation, and expenses (Strata Oncology, Genzyme)."

"We thank the patients and their families for participating in genomics, transcriptomics, and precision cancer care studies. We are thankful for expert assistance from the Translational Research Program at WCM Pathology and Laboratory Medicine (Bing He, Leticia Dizon, Yifang Liu, Mai Ho) and the WCM CLC Genomics Core Facility (Jenny Xiang). We thank Drs. Samaneh Motanagh (Weill Cornell Medicine) and Wassim Abida (Memorial Sloan Kettering Cancer Center) for their help with retrieving clinical information for some patients. We are grateful to Makayla DeJong (Seattle Cancer Care Alliance) for her help with retrieving archival pathology material. We thank Dr. Christopher Barbieri (Weill Cornell Medicine) for his valuable suggestions regarding this study. We acknowledge expert assistance from Mariana Ricca (University of Bern) in preparing the article for submission. This study was supported by the 2015–2017 Movember Foundation‐PCF Challenge Award. It has also received funding from the NIH/NCI WCM SPORE in Prostate Cancer P50‐CA211024 (H.B., F.D., M.A.R., J.M.M., B.D.R.), the Nuovo‐Soldati Foundation (J.C.), the National Science Foundation Project grants number R37 CA241486 (H.B.), and R01 CA125612 (F.D.), the Pacific Northwest Cancer Spore Award P50CA097186 and the CDMRP Award W81XWH‐18‐1‐0406 (P.N.), and the European Research Council (ERC) under the European Union's Horizon 2020 research and innovation programme (grant agreement No 648670) (F.D.). Open Access Funding provided by Universitat Bern. [Correction added on May 19, 2022, after first online publication: CSAL funding statement has been added.]"